Nasopharyngeal cancer is a rare disease in Europe, with an annual incidence of less than 1 out of 100,000 citizens. This disease has a high chemo- and radiosensitivity, allowing 5-year survival rates of 80-90% for early stages (I-II) and 60-70% for advanced stages (III-IV).
The treatment of NPC has issued numerous challenges in the last decade:
The possibility of reducing the toxicity of radiation treatment with the use of intensity-modu- lated techniques
An increase in the use of chemotherapy with a radiosensitizing function and to reduce the risk of distant metastases
The treatment of locoregional recurrence to maximize response and survival
Supportive care to reduce the toxicity induced by the cancer treatments
The best multidisciplinary management of the disease
For these reasons, this seminar on nasopharyngeal cancer will allow the various specialists involved to be up-to-date, as well as presenting the most recent therapeutic developments.
Download NPC seminar program